Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized clinical trial

Journal of Child and Adolescent Psychopharmacology

Volumn 14, Issue 3, 2004, Pages 418-425

  Mohammadi, Mohammad Reza ^a,b   Ghanizadeh, Ahmad ^a,c,d   Alaghband rad, Javad ^a   Tehranidoost, Mahdi ^a   Mesgarpour, Bita ^b   Soori, Hamid ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Natl Res Ctr of Medical Sciences   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; SELEGILINE;

ABDOMINAL PAIN; ADOLESCENT; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; EMOTION; FEMALE; HEADACHE; HUMAN; IRRITABILITY; MALE; MENTAL INSTABILITY; NAUSEA; PARENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESSNESS; SCORING SYSTEM; SIDE EFFECT; SLEEP DISORDER; TEACHER; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADOLESCENT; ANOREXIA NERVOSA; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; MALE; METHYLPHENIDATE; SELEGILINE;

EID: 8144223871     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2004.14.418     Document Type: Article

References (30)

1. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders, 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association, 1994.
2. Antkowiak R, Rajewski A: Administration of moclobemide in children with attention deficit hyperactivity disorder. Psychiatr Pol 32:751-757, 1998.
3. Barkley RA: A review of stimulant drug research with hyperactive children to stimulant drugs: A review. J Child Psychol Psychiatry 18:137-165, 1977.
4. Boix F, Qiao SW, Kolpus T, Sagvolden T: Chronic L-deprenyl treatment alters brain monoamine levels and reduces impulsiveness in an animal model of attention deficit hyperactivity disorder. Behav Brain Res 94:153-162, 1998.
5. Cyr M, Brown CS: Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder. Drugs 56:215-223, 1998.
6. DuPaul G: Parent and teacher ratings of ADHD symptoms: Psychometric properties in a community based sample. J Child Adolesc Psychopharmacol 20:245-253, 1991.
7. Ernst M, Liebenauer LL, Jons PH, Tebeka D, Cohen RM, Zametkin AJ: Selegiline in adults with attention deficit hyperactivity disorder: Clinical efficacy and safety. Psychopharmacol Bull 32:327-334, 1996.
8. Feigin A, Kurlan R, McDermott MP, Beach J, Dimitsopulos T, Brower CA, Chapieski L, Trinidad K, Como P, Jankovic J: A controlled trial of deprenyl in children with Tourette's Syndrome and attention deficit hyperactivity disorder. Neurology 64:965-968, 1996.
9. Galili-Weisstub E, Segman RH: Attention deficit and hyperactivity disorder: Review of genetic association studies. Isr J Psychiatry Relat Sci 40:57-66, 2003.
10. Greenhill LL, Abikoff HB, Arnold LE, Cantwell DP, Conners CK, Elliott G, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, March JS, Newcorn J, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wells K: Medication treatment strategies in the MTA study: Relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 35:1304-1313, 1996.
11. Greenhill LL, Findling RL, Swanson JM: A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention deficit hyperactivity disorder. Pediatrics 109:E39, 2002.
12. Greenhill LL, and Osman, BB (eds.): Ritalin: Theory and practice (2nd ed.). Larchmount, New York: Mary Ann Liebert Publishers, 2000.
13. James RS, Sharp WS, Bastain TM, Lee PP, Walter JM, Czarnolewski M, Castellanos FX: Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiatry 40:1268-76, 2001.
14. Jankovic J: Deprenyl in attention deficit associated with Tourette's Syndrome. Arch Neurol 50:286-288, 1993.
15. Kaplan HI, Sadock BJ (eds.): Synopsis of psychiatry: Behavioral sciences/clinical psychiatry (9th ed.). Philadelphia: Lippincott Williams & Wilkins, 2003.
16. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for affective disorders and schizophrenia for school-age children - present and lifetime version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988, 1997.
17. Kehoe WA: Treatment of attention deficit hyperactivity disorder in children. Ann Pharmacother 35:1130-1134, 2001.
18. Klein RG: Clinical efficacy of methylphenidate in children and adolescents. Encephale 19:89-93, 1993.
19. Lewis M (ed.): Child and adolescent psychiatry (3rd ed.). Philadelphia: Lippincott Williams and Wilkins, 2002.
20. Mohammadi MR, Kashani L, Akhondzadeh S, Izadian ES, Ohadnia S: Efficacy of theophylline compared to methylphenidate for the treatment of attention deficit hyperactivity disorder in children and adolescents: A pilot double-blind, randomized trial. J Clin Pharm Ther (In Press), 2004.
21. Parquet PJ, Servant D, Bailly D, Meurice JP: Monoamine oxidase inhibitor in the treatment of attention deficit disorder of residual type. Apropos of a case. Encephale 14:439-441, 1988.
22. Pelham WE Jr, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, Guthrie KJ, Hoover MD, Dahl RE: Relative efficacy of long-acting stimulants on children with attention deficit hyperactivity disorder: A comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 86(2):226-237, 1990.
23. Silver LB: Alternative (nonstimulant) medications in the treatment of attention deficit hyperactivity disorder in children. Pediatr Clin North Am 46:965-975, 1999.
24. Stern GM, Lees AJ, Hardie RJ, Sandler M: Clinical and pharmacological problems of deprenyl treatment in Parkinson's disease. Acta Neurol Scand Suppl 15:113-116, 1983.
25. Swanson JM, Lerner M, Williams L: More frequent diagnosis of attention deficit hyperactivity disorder. N Engl J Med 333:944, 1995.
26. Swanson JM, McBurnett K, Wigal T, Pfiffner LJ, Lerner MA, Williams L, Christian DL, Tamm L, Willcutt E, Crowley K, Clevenger W, Khouzam N, Woo C, Crinella FM, Fisher TD: Effect of stimulant medication on children with attention deficit disorder: A "review of reviews." Except Child 60:154-162, 1993.
27. Trott GE, Friese HJ, Menzel M, Nissen G: Use of moclobemide in children with attention deficit hyperactivity disorder. Psychopharmacology 106:S134-S136, 1992.
28. Trott GE, Menzel M, Friese HJ, Nissen G: Effectiveness and tolerance of the selective MAO-A inhibitor moclobemide in children with hyperkinetic syndrome (abstract). Z Kinder Jugend-psychiatr 19:248-253, 1991.
29. Vaiva G, De Lenclave MB, Bailly D: Treatment of comorbid opiate addiction and attention deficit hyperactivity disorder (residual type) with moclobemide: A case report. Prog Neuropsychopharmacol Biol Psychiatry 26:609-611, 2002.
30. Zametkin A, Rapoport JL, Murphy DL, Linnoila M, Ismond D: Treatment of hyperactive children with monoamine oxidase inhibitors. I. Clinical efficacy. Arch Gen Psychiatry 42:962-966, 1985.